Tara S Abraham

Learn More
OBJECTIVE To report the financial impact of diagnosing and treating the dermatologic toxicities (dTs) that develop in patients receiving targeted anticancer therapies. DESIGN Single-center retrospective and prospective medical record data extraction. SETTING Department of Dermatology, Northwestern University, Chicago, Illinois. PATIENTS One hundred(More)
There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium(More)
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic respiratory virus. There are no treatment options against MERS-CoV for humans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the(More)
Adoptive T-cell therapy (ACT) is an emerging paradigm in which T cells are genetically modified to target cancer-associated antigens and eradicate tumors. However, challenges treating epithelial cancers with ACT reflect antigen targets that are not tumor-specific, permitting immune damage to normal tissues, and preclinical testing in artificial xenogeneic(More)
beatriz baragaña, Irene Hallyburton, marcus C. s. Lee, Neil R. Norcross, Raffaella Grimaldi, Thomas D. Otto, William R. proto, Andrew m. blagborough, stephan meister, Grennady Wirjanata, Andrea Ruecker, Leanna m. Upton, Tara s. Abraham, mariana J. Almeida, Anupam pradhan, Achim porzelle, maría santos martínez, Judith m. bolscher, Andrew Woodland, Torsten(More)
As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was(More)
  • 1